-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to statistics, the incidence of asthma in China is 4.
1%, 30 million people suffer from asthma, and the incidence of chronic obstructive pulmonary disease is as high as 80 million
.
At present, inhaled preparations are a better treatment method in the treatment of asthma and chronic obstructive pulmonary disease
.
With the increase in the number of such patients, the industry expects that the domestic market for inhaled preparations is very broad
.
In recent years, under the background of the continuous in-depth layout of domestic pharmaceutical companies, the situation of being basically monopolized by foreign companies in the past has also been improved
.
In general, the development of the domestic inhalation preparation market is accelerating
.
Data shows that in recent years, the market for inhaled preparations in China's public medical institutions has been expanding year by year, with an annual growth rate remaining at double digits.
It exceeded 20 billion yuan in 2018 and reached 23.
68 billion yuan in 2019, a year-on-year increase of 10.
51%.
.
In the context of the fiery market of inhalation preparations, capital is also continuing to increase its weight in this field
.
On October 11th, Hangzhou Changxi Pharmaceutical announced the completion of nearly 200 million yuan in Series C financing.
This round of financing was led by Longpan Investment, and China Merchants Securities Investment and Heda Capital followed the investment.
Existing shareholders Interchina Capital followed the investment over a large proportion.
.
It is reported that the funds raised will be used to support the development of innovative inhaled drug delivery products, external business cooperation and the construction of new production bases
.
Public information shows that Changxi Pharmaceutical is a clinical stage biomedical company for the discovery, development and industrialization of new drugs that seriously affect the quality of human daily life, including respiratory diseases, and has patent-protected dry powder preparation technology and Efficient and convenient inhaler technology
.
Establish a complete industrialization system of R&D, production and sales in the fields of biomedicine and medical equipment, while pursuing strict quality, safety and value standards to serve human health
.
The chairman of Longpan Investment said that he is very optimistic about the future market potential of innovative inhalation products
.
It affirmed Changxi Pharmaceutical's formulation development technology, drug-device interactive R&D system, inhaler development evaluation system, and an experienced and resource-complementary R&D team
.
In addition to Changxi Pharmaceuticals, many pharmaceutical companies have completed 100 million yuan financing since the beginning of this year
.
For example, at the beginning of February this year, Respley announced that it had recently received nearly 200 million yuan in Series B investment
.
The financing was led by Guoke Investment, followed by investment institutions such as Yuansheng Venture Capital, Tongchuangweiye, Qianhai Fund of Funds, Tianfeng Capital, and Yifeng Capital
.
It is understood that this round of financing will be mainly used to expand the company's existing GMP production line and develop pipeline layouts such as high-end inhalation preparations and inhalation innovative drugs
.
Rispril is a company that focuses on the research and development, production and sales of respiratory system inhalation drug formulation technology and devices.
It currently has metered inhalation aerosol (MDI), dry powder inhalation (DPI), nebulizer inhalation (Nebulizer) ), Nasal Spray (NasalSpray) four major inhalation preparations R&D and production platforms, its products under development cover the full range of respiratory system products, including asthma (Asthma), chronic obstructive pulmonary disease (COPD), central nervous system disease (CNS) For many therapeutic areas with high clinical demand, it is planned that about 2 or 3 drugs can be advanced to the clinical trial stage in the next two years
.
Some analysts predict that after Changxi Pharmaceuticals completes the C round of financing, the research and development of its inhaled preparations will accelerate
.
As more and more local inhalation preparation pharmaceutical companies obtain capital investment, competition in the domestic inhalation preparation market will become more intense
.
1%, 30 million people suffer from asthma, and the incidence of chronic obstructive pulmonary disease is as high as 80 million
.
At present, inhaled preparations are a better treatment method in the treatment of asthma and chronic obstructive pulmonary disease
.
With the increase in the number of such patients, the industry expects that the domestic market for inhaled preparations is very broad
.
In recent years, under the background of the continuous in-depth layout of domestic pharmaceutical companies, the situation of being basically monopolized by foreign companies in the past has also been improved
.
In general, the development of the domestic inhalation preparation market is accelerating
.
Data shows that in recent years, the market for inhaled preparations in China's public medical institutions has been expanding year by year, with an annual growth rate remaining at double digits.
It exceeded 20 billion yuan in 2018 and reached 23.
68 billion yuan in 2019, a year-on-year increase of 10.
51%.
.
In the context of the fiery market of inhalation preparations, capital is also continuing to increase its weight in this field
.
On October 11th, Hangzhou Changxi Pharmaceutical announced the completion of nearly 200 million yuan in Series C financing.
This round of financing was led by Longpan Investment, and China Merchants Securities Investment and Heda Capital followed the investment.
Existing shareholders Interchina Capital followed the investment over a large proportion.
.
It is reported that the funds raised will be used to support the development of innovative inhaled drug delivery products, external business cooperation and the construction of new production bases
.
Public information shows that Changxi Pharmaceutical is a clinical stage biomedical company for the discovery, development and industrialization of new drugs that seriously affect the quality of human daily life, including respiratory diseases, and has patent-protected dry powder preparation technology and Efficient and convenient inhaler technology
.
Establish a complete industrialization system of R&D, production and sales in the fields of biomedicine and medical equipment, while pursuing strict quality, safety and value standards to serve human health
.
The chairman of Longpan Investment said that he is very optimistic about the future market potential of innovative inhalation products
.
It affirmed Changxi Pharmaceutical's formulation development technology, drug-device interactive R&D system, inhaler development evaluation system, and an experienced and resource-complementary R&D team
.
In addition to Changxi Pharmaceuticals, many pharmaceutical companies have completed 100 million yuan financing since the beginning of this year
.
For example, at the beginning of February this year, Respley announced that it had recently received nearly 200 million yuan in Series B investment
.
The financing was led by Guoke Investment, followed by investment institutions such as Yuansheng Venture Capital, Tongchuangweiye, Qianhai Fund of Funds, Tianfeng Capital, and Yifeng Capital
.
It is understood that this round of financing will be mainly used to expand the company's existing GMP production line and develop pipeline layouts such as high-end inhalation preparations and inhalation innovative drugs
.
Rispril is a company that focuses on the research and development, production and sales of respiratory system inhalation drug formulation technology and devices.
It currently has metered inhalation aerosol (MDI), dry powder inhalation (DPI), nebulizer inhalation (Nebulizer) ), Nasal Spray (NasalSpray) four major inhalation preparations R&D and production platforms, its products under development cover the full range of respiratory system products, including asthma (Asthma), chronic obstructive pulmonary disease (COPD), central nervous system disease (CNS) For many therapeutic areas with high clinical demand, it is planned that about 2 or 3 drugs can be advanced to the clinical trial stage in the next two years
.
Some analysts predict that after Changxi Pharmaceuticals completes the C round of financing, the research and development of its inhaled preparations will accelerate
.
As more and more local inhalation preparation pharmaceutical companies obtain capital investment, competition in the domestic inhalation preparation market will become more intense
.
